EagleClaw Capital Management’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.5M | Sell |
38,955
-119
| -0.3% | -$35.3K | 1.61% | 20 |
|
|
2025
Q4 | $10.7M | Sell |
39,074
-100
| -0.3% | -$27.2K | 1.54% | 22 |
|
|
2025
Q3 | $10.6M | Buy |
39,174
+294
| +0.8% | +$80K | 1.48% | 25 |
|
|
2025
Q2 | $10.7M | Sell |
38,880
-50
| -0.1% | -$13.6K | 1.6% | 18 |
|
|
2025
Q1 | $10.3M | Buy |
38,930
+550
| +1% | +$136K | 1.62% | 17 |
|
|
2024
Q4 | $8.91M | Buy |
38,380
+1,050
| +3% | +$241K | 1.41% | 21 |
|
|
2024
Q3 | $8.24M | Sell |
37,330
-110
| -0.3% | -$22.8K | 1.38% | 24 |
|
|
2024
Q2 | $7.36M | Buy |
37,440
+85
| +0.2% | +$17.6K | 1.32% | 26 |
|
|
2024
Q1 | $8.04M | Buy |
37,355
+515
| +1% | +$108K | 1.46% | 22 |
|
|
2023
Q4 | $7.76M | Buy |
36,840
+120
| +0.3% | +$25.6K | 1.62% | 18 |
|
|
2023
Q3 | $7.35M | Buy |
36,720
+330
| +0.9% | +$65.6K | 1.67% | 14 |
|
|
2023
Q2 | $6.74M | Buy |
36,390
+1,565
| +4% | +$289K | 1.55% | 18 |
|
|
2023
Q1 | $6.67M | Buy |
34,825
+980
| +3% | +$177K | 1.57% | 16 |
|
|
2022
Q4 | $5.69M | Sell |
33,845
-475
| -1% | -$82.5K | 1.38% | 18 |
|
|
2022
Q3 | $6.08M | Buy |
34,320
+1,265
| +4% | +$250K | 1.7% | 12 |
|
|
2022
Q2 | $6.77M | Buy |
33,055
+15
| +0% | +$3.18K | 1.84% | 12 |
|
|
2022
Q1 | $7.86M | Sell |
33,040
-200
| -0.6% | -$47K | 1.81% | 13 |
|
|
2021
Q4 | $7.59M | Buy |
33,240
+1,070
| +3% | +$235K | 1.66% | 20 |
|
|
2021
Q3 | $6.23M | Buy |
32,170
+1,710
| +6% | +$346K | 1.61% | 19 |
|
|
2021
Q2 | $6.48M | Buy |
30,460
+1,915
| +7% | +$404K | 1.68% | 16 |
|
|
2021
Q1 | $5.82M | Buy |
28,545
+1,115
| +4% | +$220K | 1.67% | 16 |
|
|
2020
Q4 | $5M | Buy |
27,430
+3,230
| +13% | +$549K | 1.59% | 23 |
|
|
2020
Q3 | $4.05M | Buy |
24,200
+1,580
| +7% | +$266K | 1.42% | 24 |
|
|
2020
Q2 | $3.67M | Buy |
22,620
+2,590
| +13% | +$464K | 1.42% | 21 |
|
|
2020
Q1 | $3.47M | Buy |
20,030
+475
| +2% | +$94.5K | 1.64% | 18 |
|
|
2019
Q4 | $3.91M | Buy |
19,555
+1,880
| +11% | +$386K | 1.43% | 19 |
|
|
2019
Q3 | $3.74M | Buy |
17,675
+1,375
| +8% | +$287K | 1.52% | 18 |
|
|
2019
Q2 | $3.17M | Buy |
16,300
+1,200
| +8% | +$221K | 1.38% | 22 |
|
|
2019
Q1 | $2.48M | Buy |
15,100
+3,625
| +32% | +$641K | 1.13% | 24 |
|
|
2018
Q4 | $2.16M | Buy |
11,475
+7,215
| +169% | +$1.33M | 1.13% | 27 |
|
|
2018
Q3 | $727K | Buy |
+4,260
| New | +$717K | 0.32% | 74 |
|
Other funds holding CME
VCM
VPM
EagleClaw Capital Management's CME Position: Q1 2026 in Review
EagleClaw Capital Management reduced its CME Group (CME) stake by 0.3% in Q1 2026, selling an estimated $35.3K and leaving 38,955 shares worth $11.5M. The position accounts for 1.61% of the portfolio, ranked #20.
EagleClaw Capital Management first reported a position in CME in Q3 2018 and has held it in 31 quarters since. 1,791 funds tracked by Wall St. Rank hold CME as of Q1 2026.
- EagleClaw Capital Management held 38,955 shares of CME Group worth $11.5M as of Q1 2026.
- EagleClaw Capital Management sold 119 CME Group shares in Q1 2026, an estimated $35.3K.
- CME Group made up 1.61% of EagleClaw Capital Management's portfolio in Q1 2026, its #20 holding.
- EagleClaw Capital Management first reported a position in CME Group in Q3 2018 and has held it in 31 quarters since.
- 1,791 funds tracked by Wall St. Rank held CME Group as of Q1 2026.
Based on EagleClaw Capital Management's 13F filing for Q1 2026, filed 8 May 2026.